Rapid Micro Biosystems, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021, compared with FY2020. This is an annual filing; the provided filing text does not give a clear standalone Q4 income statement or cash-flow summary.
Business context
The company develops and sells its Growth Direct platform, which automates microbial quality-control testing for pharmaceutical and related manufacturing. Revenue comes from systems, proprietary consumables, software, validation and service contracts, plus government-funded development work. The company completed its IPO in July 2021.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Total revenue | $23.2 million | $16.1 million | +44.5% |
| Product and service revenue | $21.6 million | $14.1 million | +53.6% |
| Recurring product and service revenue | $7.8 million | $3.9 million | +100.1% |
| Operating loss | $47.2 million | $30.5 million | Loss increased |
| Net loss | $73.5 million | $37.1 million | Loss increased 98.3% |
| Net cash used in operating activities | $55.0 million | $31.0 million | Cash use increased |
- Reported operating costs exceeded revenue by $7.7 million, implying a negative gross margin of approximately 33%. Operating loss was approximately 203% of revenue and net loss approximately 317% of revenue.
- At year-end, cash and cash equivalents were $178.4 million; short- and long-term investments totaled $25.1 million. Management reported $203.5 million of cash, cash equivalents and investments and expected these resources to fund operations and capital needs for at least 12 months after the financial statements were issued.
- No term debt remained at December 31, 2021. The company repaid its 2020 term loan in September 2021.
- Financing activities provided $216.7 million in 2021, primarily from IPO proceeds and preferred-stock financing. Investing activities used $13.3 million.
- Net loss included a $19.6 million loss from remeasurement of preferred-stock warrants before their IPO-related conversion to equity-classified common-stock warrants, and a $3.1 million debt-extinguishment loss. The warrant remeasurement was a noncash item.
Changes versus FY2020
- Product revenue rose 41.1%, mainly from more system placements and higher consumables shipments; service revenue rose 98.2%, reflecting increased validation, installation and service-contract activity. Non-commercial revenue declined 20.0% to $1.6 million.
- Operating expenses grew faster than revenue: research and development increased 49.8%, sales and marketing 98.2%, and general and administrative 79.4%. The company cited hiring and product development, commercial expansion, and public-company costs.
- Systems placed increased to 29 from 26; cumulative placements reached 116. Systems validated during the year rose to 33 from 24, with 84 validated cumulatively.
- Recurring revenue grew to 33.7% of total revenue from 24.3%. The company notes that validation and customer conversion can delay recurring consumables revenue after a system is installed.
- Basic and diluted net loss per share was $3.94 versus $126.11. The comparison is affected by the IPO and the substantially different weighted-average share count.
Outlook, commentary and risks
- No formal numeric FY2022 revenue or earnings guidance is provided in the supplied filing text. The company does not anticipate non-commercial revenue in 2022 because BARDA funding under the active contract was fully earned by Q4 2021.
- The company expected to begin beta testing a rapid sterility test with selected customers in Q2 2022. Its stated goal is to cut the traditional 14-day time to results by at least 50%; this is a development target, not reported commercial performance.
- Management describes COVID-19 restrictions and the late-2021 Omicron wave as limiting sales, shipments, installations, validation and training, and contributing to weaker-than-expected system placements late in Q4. The duration and financial impact of continuing disruption were not quantifiable.
- Key risks include continued losses and cash burn; dependence on adoption and expansion of Growth Direct; lumpy system sales, customer concentration and delays before recurring revenue; competition and product-development execution; supply-chain reliance, including a camera component whose supplier planned to discontinue production; and dependence on a single primary manufacturing and development site. A backup manufacturing facility was not yet complete.
- The company estimated its core addressable market at about $10 billion in 2022, growing to over $16 billion by 2027. These are company estimates based on assumptions, not forecasts of company revenue.
- Management concluded disclosure controls were effective at a reasonable-assurance level. The filing did not include management’s assessment or an auditor attestation on internal control over financial reporting because of newly public company transition relief.
Important facts for investors to verify
- Whether system placements, installations and validations are converting into sustained consumables and service-contract growth, and the timing of that conversion.
- Cash burn against the stated runway, especially as operating expenses and investment in sales, manufacturing and development continue to rise.
- Customer concentration and the sustainability of system orders: one customer represented 16.7% of FY2021 revenue.
- Effects of COVID-19, supply availability and qualification of an alternative camera supplier; progress toward completing backup consumables manufacturing.
- Development and validation progress for the rapid sterility test, and whether commercial launch timing and performance meet the company’s stated goals.
- How much future performance depends on market-size assumptions and growth in cell and gene therapy manufacturing.